Thalicarpine is an alkaloid found in plants of the genus Thalictrum. It has been studied for its potential anti-cancer, anti-inflammatory, and analgesic properties. Its complex structure has made its synthesis challenging, with several research groups attempting to develop efficient methods. The molecule has shown promise in preclinical studies, particularly against leukemia and colon cancer cells. Thalicarpine's effects are attributed to its ability to interfere with various cellular processes, including cell cycle regulation, apoptosis, and signal transduction pathways. Further research is ongoing to explore its therapeutic potential and to optimize its delivery and safety profile.'
thalicarpine: obtained from Thalictrum dasycarpum
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Thalictrum | genus | A plant genus of the family RANUNCULACEAE. Members contain isoquinoline alkaloids and triterpene glycosides.[MeSH] | Ranunculaceae | The buttercup plant family of the order RANUNCULALES, class MAGNOLIOPSIDA. The leaves are usually alternate and stalkless. The flowers usually have two to five free sepals and may be radially symmetrical or irregular.[MeSH] |
Thalictrum dasycarpum | species | [no description available] | Ranunculaceae | The buttercup plant family of the order RANUNCULALES, class MAGNOLIOPSIDA. The leaves are usually alternate and stalkless. The flowers usually have two to five free sepals and may be radially symmetrical or irregular.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 21470 |
CHEMBL ID | 507100 |
CHEBI ID | 9509 |
SCHEMBL ID | 674828 |
MeSH ID | M0198311 |
Synonym |
---|
taliblastine |
(6as)-9-(2-{[(1s)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-4,5-dimethoxyphenoxy)-1,2,10-trimethoxyaporphine |
CHEBI:9509 , |
(6as)-9-(2-{[(1s)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-4,5-dimethoxyphenoxy)-1,2,10-trimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline |
TBL , |
NCI60_028786 |
4h-dibenzo(de,g)quinoline, 5,6,6a,7-tetrahydro-9-(4,5-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)-1,2,10-trimethoxy-6-methyl- |
taliblastin |
6aalpha-aporphine, 9-((4,5-dimethoxy-alpha-(1beta,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl)oxy)-1,2,10-trimethoxy- |
nsc 68075 |
en 125-214 |
ny iv-34-1 |
6a.alpha.-aporphine,5-dimethoxy-.alpha.-(1.beta.,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl]oxy]-1,2,10-trimethoxy- |
thaliblastine |
4h-dibenzo[de, 5,6,6a,7-tetrahydro-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-1,2,10-trimethoxy-6-methyl- |
6a.alpha.-aporphine,5-dimethoxy-.alpha.-((s)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolyl)-o-tolyl]oxy]-1,2,10-trimethoxy- |
ny iv34 1 |
nsc-68075 |
thalicarpin |
ny-iv-34-1 |
4h-dibenzo[de, 9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, [s-(r*,r*)]- |
NSC68075 , |
4h-dibenzo[de,g]quinoline, 9-[4,5-dimethoxy-2-[[(1s)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl]methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, (6as)- |
[2-[[(1s)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl]-4,5-dimethoxy-phenoxy]-trimethoxy-methyl-[?] |
4h-dibenzo(de,g)quinoline, 9-(4,5-dimethoxy-2-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-, (s-(r*,r*))- |
C09655 |
thalicarpine |
5373-42-2 |
CHEMBL507100 |
8x1d791rf6 , |
unii-8x1d791rf6 |
(6as)-9-(4,5-dimethoxy-2-(((1s)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-4h-dibenzo(de,g)quinoline |
thalicarpine [mi] |
SCHEMBL674828 |
DTXSID90202011 |
bdbm50480321 |
(s)-9-(2-(((s)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-4,5-dimethoxyphenoxy)-1,2,10-trimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline |
Q27108417 |
nsc 68075; taliblastine; thaliblastine |
(6as)-9-[2-[[(1s)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl]-4,5-dimethoxyphenoxy]-1,2,10-trimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline |
Class | Description |
---|---|
isoquinolines | A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives. |
bisbenzylisoquinoline alkaloid | A type of benzylisoquinoline alkaloid whose structures are built up of two benzylisoquinoline units linked by ether bridges. Various structural patterns resulting from additional bridging between the two units by direct carbon-carbon bridging or by methylenedioxy groups are common. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID333842 | Cytotoxicity against human KB cells | |||
AID397122 | Inhibition of HIV1 RT | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (14.29) | 18.7374 |
1990's | 3 (42.86) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.09) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |